Microsaic had a challenging FY’16 performance as it lost traction with one of its key OEM partners in H2. Despite disappointing sales, the group controlled costs and cash burn and year end cash of £5.7m was in line with expectations. In addition, the product has been strengthened, aligning it more towards the biopharma strategy unveiled at the fundraising last August. Successful execution of this strategy should drive higher volume for its product in the future. The company is valued at less tha ....
21 Mar 2017
N+1 Singer - Microsaic Systems - Challenges in 2016, strategy remains in place
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Microsaic Systems - Challenges in 2016, strategy remains in place
Microsaic Systems plc (MSYS:LON) | 1.2 0 0.0% | Mkt Cap: 0.12m
- Published:
21 Mar 2017 -
Author:
Tintin Stormont -
Pages:
5
Microsaic had a challenging FY’16 performance as it lost traction with one of its key OEM partners in H2. Despite disappointing sales, the group controlled costs and cash burn and year end cash of £5.7m was in line with expectations. In addition, the product has been strengthened, aligning it more towards the biopharma strategy unveiled at the fundraising last August. Successful execution of this strategy should drive higher volume for its product in the future. The company is valued at less tha ....